- Home
- SRTS vs BCAB Comparison
SRTS vs BCAB Comparison
Compare SRTS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRTS | BCAB |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5M | 71.6M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SRTS | BCAB |
|---|---|---|
| Price | $4.78 | $0.36 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $8.00 | $1.00 |
| AVG Volume (30 Days) | 73.5K | ★ 1.9M |
| Earning Date | 02-04-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,609,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $29.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.03 | $0.24 |
| 52 Week High | $9.08 | $1.43 |
Technical Indicators
Market Signals| Indicator | SRTS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 74.72 | 28.67 |
| Support Level | $4.30 | $0.36 |
| Resistance Level | $4.64 | $0.82 |
| Average True Range (ATR) | 0.24 | 0.11 |
| MACD | 0.09 | -0.04 |
| Stochastic Oscillator | 95.08 | 1.08 |
Price Performance
Historical ComparisonAbout SRTS Sensus Healthcare Inc.
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.